The involvement of BIM in sunitinib activity has been suggested by several prior animal and in vitro studies—Naik et al. demonstrated that destruction of tumor vasculature by VEGF-blocking antibodies was BIM-dependent [29] and Yang et al. noted that there was upregulation of BIM along with other proapoptotic genes in human medulloblastoma cell lines treated with sunitinib [30]. This evidence concerns the gene BCL2L11 and medulloblastoma.